SciSparc Secures European Patent for Tourette Syndrome Treatment
Ticker: SPRC · Form: 6-K · Filed: Jun 3, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, pharmaceuticals, intellectual-property, tourettes-syndrome
TL;DR
SciSparc just got a European patent for a CBD/PEA combo to treat Tourette's. Big IP win!
AI Summary
SciSparc Ltd. announced on May 31, 2024, that it has been granted a European patent for its novel pharmaceutical composition. This patent covers a combination of Cannabidiol (CBD) and Palmitoylethanolamide (PEA) for the treatment of Tourette Syndrome and related disorders. The company believes this patent provides a significant strategic advantage in its ongoing development efforts.
Why It Matters
This patent grant strengthens SciSparc's intellectual property portfolio and could lead to exclusive market rights for a novel treatment for Tourette Syndrome, potentially impacting patient care and the company's future revenue streams.
Risk Assessment
Risk Level: medium — While a patent is positive, the actual commercial success and regulatory approval of the pharmaceutical composition remain uncertain.
Key Players & Entities
- SciSparc Ltd. (company) — The company filing the report and announcing the patent.
- May 31, 2024 (date) — Date of the press release announcing the patent grant.
- European patent (patent) — The intellectual property granted to SciSparc.
- Cannabidiol (CBD) (drug) — One of the active components in the patented pharmaceutical composition.
- Palmitoylethanolamide (PEA) (drug) — The other active component in the patented pharmaceutical composition.
- Tourette Syndrome (medical_condition) — The condition the patented composition is intended to treat.
FAQ
What is the specific scope of the European patent granted to SciSparc Ltd.?
The European patent covers a novel pharmaceutical composition comprising Cannabidiol (CBD) and Palmitoylethanolamide (PEA) for the treatment of Tourette Syndrome and related disorders.
When was the press release announcing this patent grant issued?
The press release was issued on May 31, 2024.
What is the primary indication for the patented pharmaceutical composition?
The primary indication is for the treatment of Tourette Syndrome and related disorders.
What is the significance of this patent for SciSparc Ltd.?
SciSparc Ltd. considers the patent grant to provide a significant strategic advantage in its development efforts.
Under which SEC form is this information being reported?
This information is being reported on a Form 6-K.
Filing Stats: 304 words · 1 min read · ~1 pages · Grade level 8.5 · Accepted 2024-06-03 07:13:53
Filing Documents
- ea0207099-6k_scisparc.htm (6-K) — 12KB
- ea020709902ex99-1_scisparc.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-048774.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: June 3, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3